U.S. Viral Vector and Plasmid DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report: By Vector Type, By Disease, By Workflow, By Application, By End-Use - Market Forecast, 2024

Description

List of Tables

The U.S. viral vector and plasmid DNA manufacturing market size is expected to reach USD 11,315.21 million by 2032, according to a new study by Polaris Market Research. The report "U.S. Viral Vector and Plasmid DNA Manufacturing Market Size, Share, Trends, Industry Analysis Report, By Vector Type, By Disease (Cancer, Genetic Disorders, Infectious Diseases, Others), By Workflow, By Application, By End-Use, Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of hereditary and infectious disorders has seen a substantial rise in the U.S. According to the National Institutes of Health, in 2019, approximately 100,000 individuals were diagnosed with sickle cell anemia in the U.S. The increasing utilization of gene therapy for treating viral infections like adeno-associated viruses, herpes simplex viruses, poxviruses, and retroviruses is expected to drive the adoption of gene therapies, thereby boosting the market growth for the production of viral vectors and plasmid DNA during the forecast period.

The global industry is experiencing a rise in the number of patients opting for gene therapy, leading to an increased demand for plasmid DNA for the research and development of gene therapy. Therefore, the production of plasmid DNA (pDNA) is crucial for lentivirus, Adeno-associated virus (AAV), and other viral vector systems. Furthermore, the prevalence of various infectious diseases on a worldwide scale has contributed to the expansion of the U.S. viral vectors and plasmid DNA manufacturing market share.

Furthermore, the U.S. market for viral vector and plasmid DNA manufacturing is undergoing substantial expansion due to the increasing need for vaccines and advanced therapeutic treatments. Government support and funding are instrumental in driving this growth. As a result, there has been a significant increase in the market share of U.S. viral vectors and plasmid DNA manufacturing.

U.S. Viral Vector and Plasmid DNA Manufacturing Market Report Highlights

In 2023, the cancer segment accounted for the largest revenue share in the U.S. viral vector and plasmid DNA manufacturing market as the rising prevalence of cancer has heightened the need for advanced treatments such as gene therapies and oncolytic viral therapies, which heavily utilize viral vectors and plasmid DNA.

The pharmaceutical and biopharmaceutical companies category is expected to grow significantly over the forecast period. This is because gene therapies are expanding beyond rare genetic disorders to more common conditions, including cancers, cardiovascular diseases, and infectious diseases.

The U.S. key market players include Bio-Rad Laboratories, Inc., Catalent Inc., Charles River Laboratories (Cobra Biologics), Genezen, Promega Corporation, RegenxBio, Inc., Revvity (SIRION Biotech), Thermo Fisher Scientific, Inc., Virovek Incorporation, and Waisman Biomanufacturing.

Polaris Market Research has segmented the U.S. viral vector and plasmid DNA manufacturing market report based on vector type, disease, workflow, application, and end-use.

U.S. Viral Vector and Plasmid DNA Manufacturing, Vector Type Outlook (Revenue - USD Million, 2019 - 2032)

Adeno-Associated Virus (AAV)
Adenovirus
Lentivirus
Others
Plasmids
Retrovirus

U.S. Viral Vector and Plasmid DNA Manufacturing, Disease Outlook (Revenue - USD Million, 2019 - 2032)

Cancer
Genetic Disorders
Infectious Diseases
Others

U.S. Viral Vector and Plasmid DNA Manufacturing, Workflow Outlook (Revenue - USD Million, 2019 - 2032)

Upstream Manufacturing
Vector Amplification & Expansion
Vector Recovery/Harvesting
Downstream Manufacturing
Fill Finish
Purification

U.S. Viral Vector and Plasmid DNA Manufacturing, Application Outlook (Revenue - USD Million, 2019 - 2032)

Antisense & RNAi Therapy
Cell Therapy
Gene Therapy
Research Applications
Vaccinology

U.S. Viral Vector and Plasmid DNA Manufacturing, End-Use Outlook (Revenue - USD Million, 2019 - 2032)

Pharmaceutical and Biopharmaceutical Companies
Research Institutes

Product Code: PM5000

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. U.S. Viral Vector and Plasmid DNA Manufacturing Insights

4.1. U.S. Viral Vector and Plasmid DNA Manufacturing - Application Snapshot
4.2. U.S. Viral Vector and Plasmid DNA Manufacturing Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. The Rising Demand for Gene and Cell Therapies is Driving Market Growth
  - 4.2.1.2. The Growing Technological Advancements Drives Market Outlook
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Production Costs
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. U.S. Viral Vector and Plasmid DNA Manufacturing Application Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vector Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vector Type, 2019-2032 (USD Million)
5.3. by Adeno-Associated Virus (AAV)
- 5.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Adeno-Associated Virus (AAV), 2019-2032 (USD Million)
5.4. Adenovirus
- 5.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Adenovirus, 2019-2032 (USD Million)
5.5. Lentivirus
- 5.5.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Lentivirus, 2019-2032 (USD Million)
5.6. Plasmids
- 5.6.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Plasmids, 2019-2032 (USD Million)
5.7. Retrovirus
- 5.7.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Retrovirus, 2019-2032 (USD Million)
5.8. Others
- 5.8.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Others, 2019-2032 (USD Million)

6. U.S. Viral Vector and Plasmid DNA Manufacturing, by Disease

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Disease, 2019-2032 (USD Million)
6.3. Cancer
- 6.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Cancer, 2019-2032 (USD Million)
6.4. Genetic Disorders
- 6.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Genetic Disorders, 2019-2032 (USD Million)
6.5. Infectious Diseases
- 6.5.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Infectious Diseases, 2019-2032 (USD Million)
6.6. Others
- 6.6.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Others, 2019-2032 (USD Million)

7. U.S. Viral Vector and Plasmid DNA Manufacturing, by Workflow

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Workflow, 2019-2032 (USD Million)
7.3. Upstream Manufacturing
- 7.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Upstream Manufacturing, 2019-2032 (USD Million)
- 7.3.2. Vector Amplification & Expansion
  - 7.3.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vector Amplification & Expansion, 2019-2032 (USD Million)
- 7.3.3. Vector Recovery/Harvesting
  - 7.3.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vector Recovery/Harvesting, 2019-2032 (USD Million)
7.4. Downstream Manufacturing
- 7.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Downstream Manufacturing, 2019-2032 (USD Million)
- 7.4.2. Fill Finish
  - 7.4.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Fill Finish, 2019-2032 (USD Million)
- 7.4.3. Purification
  - 7.4.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Purification, 2019-2032 (USD Million)

8. U.S. Viral Vector and Plasmid DNA Manufacturing, by Application

8.1. Key Findings
8.2. Introduction
- 8.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Application, 2019-2032 (USD Million)
8.3. Antisense & RNAi Therapy
- 8.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Antisense & RNAi Therapy, 2019-2032 (USD Million)
8.4. Cell Therapy
- 8.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Cell Therapy, 2019-2032 (USD Million)
8.5. Gene Therapy
- 8.5.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Gene Therapy, 2019-2032 (USD Million)
8.6. Research Applications
- 8.6.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Research Applications, 2019-2032 (USD Million)
8.7. Vaccinology
- 8.7.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Vaccinology, 2019-2032 (USD Million)

9. U.S. Viral Vector and Plasmid DNA Manufacturing, by End-Use

9.1. Key Findings
9.2. Introduction
- 9.2.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by End-Use, 2019-2032 (USD Million)
9.3. Pharmaceutical and Biopharmaceutical Companies
- 9.3.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Pharmaceutical and Biopharmaceutical Companies, 2019-2032 (USD Million)
9.4. Research Institutes
- 9.4.1. U.S. Viral Vector and Plasmid DNA Manufacturing, by Research Institutes, 2019-2032 (USD Million)

10. Competitive Landscape

10.1. Expansion and Acquisition Analysis
- 10.1.1. Expansion
- 10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

11.1. Bio-Rad Laboratories, Inc.
- 11.1.1. Company Overview
- 11.1.2. Financial Performance
- 11.1.3. Product Benchmarking
- 11.1.4. Recent Development
11.2. Catalent Inc.
- 11.2.1. Company Overview
- 11.2.2. Financial Performance
- 11.2.3. Product Benchmarking
- 11.2.4. Recent Development
11.3. Charles River Laboratories (Cobra Biologics)
- 11.3.1. Company Overview
- 11.3.2. Financial Performance
- 11.3.3. Product Benchmarking
- 11.3.4. Recent Development
11.4. Genezen
- 11.4.1. Company Overview
- 11.4.2. Financial Performance
- 11.4.3. Product Benchmarking
- 11.4.4. Recent Development
11.5. Promega Corporation
- 11.5.1. Company Overview
- 11.5.2. Financial Performance
- 11.5.3. Product Benchmarking
- 11.5.4. Recent Development
11.6. RegenxBio, Inc.
- 11.6.1. Company Overview
- 11.6.2. Financial Performance
- 11.6.3. Product Benchmarking
- 11.6.4. Recent Development
11.7. Revvity (SIRION Biotech)
- 11.7.1. Company Overview
- 11.7.2. Financial Performance
- 11.7.3. Product Benchmarking
- 11.7.4. Recent Development
11.8. Thermo Fisher Scientific, Inc.
- 11.8.1. Company Overview
- 11.8.2. Financial Performance
- 11.8.3. Product Benchmarking
- 11.8.4. Recent Development
11.9. Virovek Incorporation
- 11.9.1. Company Overview
- 11.9.2. Financial Performance
- 11.9.3. Product Benchmarking
- 11.9.4. Recent Development
11.10. Waisman Biomanufacturing
- 11.10.1. Company Overview
- 11.10.2. Financial Performance
- 11.10.3. Product Benchmarking
- 11.10.4. Recent Development